drugset / Trial / NCT04551586

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

NCT04551586

Phase 1 Completed 28 enrolled Alexion Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

This will be an open-label, 3-sequence, 3-period crossover study in healthy adult participants to assess the relative bioavailability of ACH-0145228 when administered as an immediate release tablet versus powder-in-capsule.

Timeline

Start
2020-06-26
Primary completion
2020-10-19
Completion
2020-10-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Vemircopan Small molecule 240 mg Oral

Indications

No indication recorded.